ライフサイエンスコーパス: iodo

1 5-Iodo-1,2,3-triazole (iodotriazole) can be prepared from

2 4-(1'-Cyclohexenyl)-5-iodo-1,2,3-triazole and 4-phenyl-1,2,4-triazoline-3,5-di

3 the amine compromises the selectivity for 5-iodo-1,2,3-triazole by promoting the formation of 5-prot

4 mechanistic model is formulated in which a 5-iodo-1,2,3-triazole is formed via iodination of a copper

5 iological evaluation suggests that 5-[(125)I]iodo-1,2,3-triazoles are resistant to deiodination in vi

6 cies and triiodide ion in the formation of 5-iodo-1,2,3-triazoles than that of the pure forms of copp

7 kynes, and [(125)I]iodide to yield 5-[(125)I]iodo-1,2,3-triazoles.

8 ing reaction of propargylic stannanes with 5-iodo-1,3-oxazoles to produce 1,1-disubstituted allenes (

9 rganic azide and terminal alkyne to afford 5-iodo-1,4-disubstituted-1,2,3-triazoles.

10 2,2-difluoro-1-iodoethene and 2,2-difluoro-1-iodo-1-(2'-methoxyethoxymethoxy)ethene.

11 regioselective annulation of allenes with 3-iodo-1-alkylindole-2-carboxylic acids is described.

12 in good overall yield in three steps from 2-iodo-1-naphthoic acid and enantiopure beta-amino alcohol

13 ion of 4-methylanisole and alkylation with 5-iodo-1-pentene, followed by intramolecular Friedel-Craft

14 ereogenic cuprate reagent with (E)-4-bromo-1-iodo-1-trimethylsilyl-1-butene with retention of configu

15 sequential oxidation reaction of cyclized 7-iodo-12-phenylindeno[2,1-alpha]phenalene (ipp) with mole

16 To test this hypothesis, the oxidation of 12-iodo-, 12-bromo-, and 12-chlorododecanoic acids by recom

17 nist (1-butylpiperidin-4-yl)methyl-8-amino-7-iodo[(123)I]-2,3-dihydrobenzo[b][1,4]diox ine-5-carboxyl

18 binding site or receptor, we synthesized 20-iodo-14,15-epoxyeicosa-8(Z)-enoyl-3-azidophenylsulfonami

19 amides by the aminocarbonylation of 5-aryl-4-iodo-1H-imidazoles using ex situ generation of CO from M

20 nterparts and allows the synthesis of both 3-iodo-1H-indenes (from beta-alkyl-beta-alkyl/aryl-o-(alky

21 2CO3 at room temperature to provide 1-acyl-4-iodo-1H-pyrazoles.

22 3-iodo-1H-pyrrolo[3',2':4,5]imidazo-[1,2-a]pyridines and [

23 ne (2a) and 3-N-benzoyl-3',5'-di-O-benzoyl-5-iodo-2'-deoxy-2'-fluoroarabinouridine (2b) with unactiva

24 ernate base pairings of OdG, 8-chloro- and 8-iodo-2'-deoxyguanosine were incorporated into oligonucle

25 coupling of 3-N-benzoyl-3',5'-di-O-benzoyl-5-iodo-2'-deoxyuridine (2a) and 3-N-benzoyl-3',5'-di-O-ben

26 ads to increased incorporation of 5-[(125)I]-iodo-2'-deoxyuridine ([(125)I]dUrd) into DNA.

27 ommitted, slowly cycling cells by tracking 5-iodo-2'-deoxyuridine (IdU) label-retaining cells (LRCs)

28 oduced with 5-azacytidine (AzaC) and with 5'-iodo-2'-deoxyuridine (IUdR); none was detected with sodi

29 nist (1-butylpiperidin-4-yl)methyl 8-amino-7-iodo-2,3-dihydrobenzo[b][1,4]dioxine-5-carboxylate (1, S

30 orophenoxy)propyl]-4-methyl-4-piperidinyl]-5-iodo-2- methoxybenzamide (123I-5-I-R91150).

31 (123)I-IMPY (6-iodo-2-(4'-dimethylamino-)phenyl-imidazo[1,2-a]pyridine)

32 ashira reaction for cross-coupling between 1-iodo-2-(phenylethynyl)benzene (7) and 1-(2-propynyl)-1H-

33 nedioic acid (OPA) carbamate [(18)F]23 and 4-iodo-2-[(18)F]fluorobenzoyllysine OPA carbamate [(18)F]2

34 evaluation led to the identification of 4-[4-iodo-2-[(5-quinoxalinylsulfonyl)amino]benzoyl]-morpholin

35 In the presence of indium metal, 3-iodo-2-[(trimethylsilyl)methyl]propene (1) reacts with s

36 reacting (11)C-cyanide ion with protected 4-iodo-2-amino-butanoic ester, the key intermediate was ob

37 via a palladium-catalyzed dimerization of 1-iodo-2-arylethynyl-acenaphthylenes.

38 include the chemoselective lithiation of a 1-iodo-2-bromoolefin, the introduction of the side chains

39 nitrobenzene and a 4,5-trans-disubstituted 2-iodo-2-cyclohexen-1-one, engaged in a tandem reductive c

40 inistration of 5-chloro-2-deoxyuridine and 5-iodo-2-deoxyuridine indicated that all HSCs segregate th

41 uorophenyl)propyl]-4-methylpiperidin-4-yl]-5-iodo-2-methoxy benzamide) and the influence of ketamine

42 diethylamino-ethyl)-4-(4-fluoro-benzamido)-5-iodo-2-methoxy-benzamide (MIP-1145), was evaluated for i

43 wing N(6) derivatives: 2,5-dichlorobenzyl, 5-iodo-2-methoxybenzyl, trans-2-phenyl-1-cyclopropyl, and

44 completed via asymmetric allylation of (E)-3-iodo-2-methylprop-2-enal followed by oxidative cleavage

45 3-Iodo-2-naphthols have also been prepared in excellent yi

46 ygen derived from air, yielding 12-hydroxy-7-iodo-2-phenylindeno[2,1-alpha]phenalen-1(12H)-one (hipp)

47 ibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30).

48 esence of specific Raf-1 inhibitor GW5074 (5-iodo-3-[(3,5-dibromo-4-hydroxyphenyl) methylene]-2-indol

49 mission computed tomography ligand [(123)I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine.

50 (123)I-5-IA-85380 ((123)I-5-IA; [(123)I]-5-iodo-3-[2(S)-azetidinylmethoxy]pyridine) is a promising

51 cetate (5) and p-methoxybenzyl 2,6-dideoxy-2-iodo-3-C-methyl-alpha-mannopyranoside (11).

52 (2'R)-5'-(2-(125)I-iodo-3-furanyl)spiro[1-azabicyclo[2.2.2]octane]-3,2'(3'

53 -2(1H)-yl)butyl)-2-(2-[18F]-fluoroethox y)-5-iodo-3-methoxybenzamide ([18F]3f) are acceptable compoun

54 e 7-methylbenziodoxolone ring system using 2-iodo-3-methylbenzoic acid as starting compound.

55 nthesis of masked 2,3-diaminoindole 1 from 2-iodo-3-nitro-1-(phenylsulfonyl)indole (2) has been devel

56 ually all high affinity IgG anti-4-hydroxy-5-iodo-3-nitrophenyl acetyl in the second week.

57 clusters and production of anti-4-hydroxy-5-iodo-3-nitrophenyl acetyl.

58 the order of affinity was 4'-bromo (3d) > 4'-iodo (3e) = 4'- chloro (3c) > 4'-methyl (3f) > 4'-fluoro

59 cells was sensitive to inhibition by trans-4-iodo, 4'-boranyl-chalcone, consistent with HDM2-catalyzi

60 onyl]methyl reserpate (AIPPMER), 18-O-[N-(3'-iodo-4'-azidophenethyl)glycyl]methyl reserpate (IAPEGlyM

61 These compounds are 18-O-[3-(3'-iodo-4'-azidophenyl)-propionyl]methyl reserpate (AIPPMER

62 ]methyl reserpate (IAPEGlyMER), and 2-N-[(3'-iodo-4'-azidophenyl)-propionyl]tetrabenazine (TBZ-AIPP).

63 osure of the vinyllithium derived from (Z)-1-iodo-4,4,5-trimethyl-1,5-hexadiene by lithium-iodine exc

64 Diastereomers of N-(cyclohex-2-enyl)-N-(2-iodo-4,6-dimethylphenyl)acetamides with an additional or

65 ter-insoluble 2-(2'-hydroxyphenyl)-6-[(125)I]iodo-4-(3H)-quinazolinone ((125)IQ(2-OH)).

66 luble 2-(2',4'-dihydroxyphenyl)-6-[127I/125I]iodo-4-(3H)-quinazolinone (127IQ2-OH,4-OH (2)/125IQ2-OH,

67 rodrug ammonium 2-(2'-phosphoryloxyphenyl)-6-iodo-4-(3H)-quinazolinone (IQ(2-P)) was docked in silico

68 Ammonium 2-(2',4'-diphosphoryloxyphenyl)-6-iodo-4-(3H)-quinazolinone (IQ2-P,4-P), having the most f

69 analog 1-O-hexadecanoyl-2-O-[9-[[[2-[(125)I]iodo-4-(trifluoromethyl-3H-diazirin-3-yl)ben zyl]oxy]car

70 e probe 1-O-hexadecanoyl-2-O-[9-[[[2-[(125)I]iodo-4-(trifluoromethyl-3H-diazirin-3-yl)ben zyl]oxy]car

71 oxyphenyl)tropane-2beta-carboxylic acid 2-(3-iodo-4-aminophenyl)ethyl ester (8i) with an IC(50) value

72 cocaine derivative and photoprobe 3-[ (125)I]iodo-4-azidococaine ([ (125)I]IACoc) binds to the sigma-

73 The cocaine photoaffinity label 3-iodo-4-azidococaine ([125I]IACoc) binds to the sigma-1 r

74 lly available 4-methoxy-2-nitroaniline and 1-iodo-4-methoxy-2-nitrobenzene.

75 r induction using N,N-diethyl-2-(2-(3-(125)I-iodo-4-methoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrim i

76 anilides and alkyl-/arylthioanilides using 1-iodo-4-nitrobenzene as catalyst and oxone as an inexpens

77 fically labeled using (111)In-DOTA or (125)I-iodo-((4-hydroxyphenyl)ethyl) maleimide (HPEM).

78 d via palladium-catalyzed carbonylation of 2-iodo-5-methoxyaniline (4) with thiazolylacetylene 5.

79 mesylate [WIN 55,212-2 (WIN)] and (R,S)-3-(2-iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1H

80 lated with IgE-ICs consisting of 4-hydroxy-3-iodo-5-nitrophenylacetyl (NIP)-specific IgE JW8 and NIP-

81 P2Y1 receptor antagonist (1R,2S,4S,5S)-4-[2-iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicy

82 phosphate (MRS 2179), and (1R,2S,4S,5S)-4-[2-Iodo-6-(methylamino)-9H-purin-9-yl]-2-(phosphonooxy)bicy

83 potent of these compounds is ethyl 2-(N-((4-iodo-6-methoxypyrimidin-2-yl)carbamoyl)sulfamoyl)benzoat

84 ad led to the identification of N(4)-butyl-5-iodo-6-methylpyrimidine-2,4-diamine as a pure TLR8 agoni

85 mbination of GM-CSF plus the MIF inhibitor 4-iodo-6-phenyl-pyrimidine achieved the best reprogramming

86 ogue MIF are biophysically very different, 4-iodo-6-phenylpyrimidine (4-IPP) forms a covalent bond wi

87 studies further reveal that this compound, 4-iodo-6-phenylpyrimidine (4-IPP), is approximately 5x to

88 Notably, the small molecule MIF inhibitor 4-iodo-6-phenylpyrimidine inhibits MIF secretion by target

89 discovered MIF small molecule antagonist, 4-iodo-6-phenylpyrimidine, recapitulates MIF deficiency in

90 the photo-affinity ligand 2-azido-3-[(125)I]iodo-7,8-dibromodibenzo-p-dioxin and liver cytosol isola

91 l acrylate to 5-iodoracil, 5-iodocytosine, 7-iodo-7-deazaadenine, and 7-iodo-7-deazaguanine 2'-deoxyr

92 5-iodocytosine, 7-iodo-7-deazaadenine, and 7-iodo-7-deazaguanine 2'-deoxyribonucleoside 5'-O-monophos

93 ,5S)-tert-butyl 2-(benzyloxycarbonylamino)-4-iodo-7-oxo-6-azabicyclo[3.2.1]octane-6-carboxylate 11.

94 5-(123)I-iodo-85380 ((123)I-5-IA) is used to quantitate high-affi

95 um salts add selectively to C6 of 6-chloro-8-iodo-9-(2,3,5-tris-O-tert-butyldimethylsilyl-beta-d-ribo

96 t compound, were synthesized from 6-chloro-2-iodo-9-methyl-9H-purine (2) by selective C-C bond format

97 Conversely, 5-iodo-A-85380, sazetidine-A, varenicline, alpha-conotoxin

98 sidues with a novel reagent, 2,4-dibromo-(2'-iodo)acetanilide.

99 DI MS analysis kit containing N-succinimidyl iodo-acetate, suberic acid bis(3-sulfo-N-hydroxysuccinim

100 either novel alpha-iodo-N-Ts-imines or alpha-iodo-aldehydes in high yield.

101 ents and other nucleophiles delivered (2Z)-2-iodo allylic alcohols.

102 hed by alcohol, water, or NH(3) to give beta-iodo-alpha,alpha,beta,beta-tetrafluorocarboxylic acid de

103 ylation of phenylphosphine borane with gamma-iodo-alpha-amino ester reagents under phase-transfer cat

104 nation and diastereoselective intramolecular iodo-amination, led to highly convergent total syntheses

105 )boronatophenylphosphine with beta- or gamma-iodo amino acid derivatives which are prepared from L-se

106 of the phosphine was performed using either iodo amino ester or carboxylic acid derivatives.

107 methylpropa namide 11 or the corresponding 5-iodo analog 14 via Sonogashira couplings with appropriat

108 ue 3e (IC(50) = 0.12 nM) and the 3'-bromo-4'-iodo analogue 3i (K(i) = 0.14 nM) are the most potent an

109 The high affinity of the N-methyl-3'-iodo analogue 4 combined with its weak agonist and poten

110 he 3'-fluoro analogue 3a and the N-methyl-3'-iodo analogue 4 showed AD(50) values of 0.07 and 0.04 mi

111 id and 12-oxododecanoic acid, whereas the 12-iodo analogue is very poorly oxidized.

112 henols rather of the more expensive bromo or iodo analogues makes this procedure environmentally conv

113 ctivity, including ribose ring constraint, 5-iodo and 4-alkyloxyimino modifications, and phosphate mo

114 gations proved the structural equivalence of iodo and cyano Gilman cuprates and their subsequential i

115 ta-substitutions on the aniline ring such as iodo and cyano increased reactivity with dansyl-GCVLS an

116 NAr reactions with 6-(fluoro, chloro, bromo, iodo, and alkylsulfonyl)purine nucleosides and nitrogen,

117 Fluoro, chloro, bromo, iodo, and gem-dihaloalkenes are viable substrates for th

118 ddition of N-formyl derivatives of 2-amino-3-iodo- and 3-amino-4-iodopyridines to acetylenes activate

119 tter nucleophile than the corresponding beta-iodo- and beta-chloroenones 9a,c; (2) (Me)2Phen(OMe)2.Ni

120 tion of free (N-H)-indoles and pyrroles with iodo- and bromoarene donors.

121 are operonic and inducible with 4-chloro-, 4-iodo-, and 4-bromobenzoate.

122 shows significant inhibition by 4-bromo-, 4-iodo-, and 4-fluorobenzoate and mild inhibition by 3-chl

123 Aryl halides, such as chloro-, bromo-, iodo-, and fluorobenzene, behave differently under the s

124 situ with TBAF and coupled to the 3-bromo-5-iodo arene using the iodo selective Pd(tri-2-furylphosph

125 thynyl arene and the other being a 3-bromo-5-iodo arene.

126 Generation of a [hydroxy(tosyloxy)iodo]arene from a functionalized (diacetoxyiodo)arene in

127 rting from simple and commercially available iodo arenes and aldehydes, for the synthesis of a wide v

128 e synthesis of various [bis(trifluoroacetoxy)iodo]arenes, ArI(OCOCF(3))(2).

129 l tertiary phosphines bearing an o-bromo (or iodo)aryl substituent is described.

130 activity, which is further enhanced when an iodo, aryl, heteroaryl, t-butyl, or cyclopentyl substitu

131 N-(R)-1-Aza-bicyclo[2.2.2]oct-3-yl-4-(125)I-iodo-benzamide 3 was synthesized by halogen exchange of

132 vity of enol esters toward [hydroxy(tosyloxy)iodo]benzene (HTIB) was assessed.

133 alent iodine(III) reagent, [hydroxy(tosyloxy)iodo]benzene (Koser's reagent), has been developed.

134 emperature mediated by [bis(trifluoroacetoxy)iodo]benzene (PIFA) and N-bromosuccinimide (NBS) using c

135 azatriphenylene, using [bis(trifluoroacetoxy)iodo]benzene is reported.

136 further oxidized with [bis(trifluoroacetoxy)iodo]benzene to give stable benziporphyrin derivatives.

137 Thus, reaction of 2-bromo or 2-iodo benzoate esters with amdidines afforded substituted

138 h enantioselection is the finding that ortho-iodo benzoic acid salts of the chiral copper(II) bis(oxa

139 Coupling of 2-iodo benzoic acids with enolates that were produced in s

140 ng Auger emitter 2-[3-[1-carboxy-5-(4-(125)I-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ((1

141 We prepared 2-[3-[1-carboxy-5-(4-[(125)I]iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ([(

142 The preparation of challenging 2-deoxy-2-iodo-beta-D-allo precursors of 2-deoxy-beta-D-ribo-hexop

143 Unexpectedly, all reactions provided 2-iodo-beta-D-ketopyranosides in high yields and excellent

144 beta-glycosidation reaction of 2,6-dideoxy-2-iodo-beta-glucopyranosyl acetate (5) and p-methoxybenzyl

145 3-(4'-Azido-3'-iodo-biphenyl-4-yl)-8-methyl-8-aza-bicyclo[3.2.1]octane-

146 -tetramethyl-4-bora-3a,4a-diaza-s-in dacene (iodo-BODIPY) via a phenylacetylene linker.

147 s an efficient method for the preparation of iodo-, bromo-, and azido-derivatives via dediazoniation.

148 koxide followed by tandem diastereoselective iodo-, bromo-, or chlorocyclopropanation to furnish halo

149 e potential incorporation of alkyl copper in iodo but not in cyano Gilman cuprates during the reactio

150 oranes outperform the traditionally utilized iodo-carborane species.

151 in 100% iodine atom economy for the reported iodo-cofunctionalization of alkenes.

152 )CO(2)I is utilized for the synthesis of 1,2-iodo-cofunctionalized derivatives of a variety of alkene

153 the palladium-aryl bond in arylpalladium(II) iodo complexes giving rise to atropisomers, as well as t

154 of XeF(2) at the iodo ligand of Pt(II) aryl iodo complexes to generate I-F species can be operative

155 A series of diphosphine Pt(II) aryl iodo complexes were reacted with XeF(2) to cleanly produ

156 The iodo compound 9b has nanomolar affinity for mGlu(5) and

157 ction periods ( approximately 50 min for the iodo compound and approximately 6 h for the fluoro analo

158 ding interactions between electron-deficient iodo compounds and Lewis bases.

159 The solid state structures of the chloro and iodo congeners establish short Zr N and elongated N N bo

160 mino, ester, chloro, trifluoromethyl, bromo, iodo, cyano, and fluoro groups, are tolerated.

161 with nitromethane followed by electrophilic iodo cyclization of the resulting 2-nitro-1-(2-(alkynyl)

162 ra, and Heck C-C cross-coupling reactions of iodo derivatives 1c, 1d, and 2d were also successful and

163 ynthesis of the corresponding 1-chloro and 1-iodo derivatives have been achieved using the correspond

164 The bromo and iodo derivatives of these molecules are useful tools for

165 nal and biological use, including fluoro and iodo derivatives with potential radiodiagnostic ((18)F)

166 nctional method support that, in the case of iodo derivatives, homolytic thienyl-I bond fragmentation

167 ed are four synthetically valuable bromo and iodo derivatives.

168 [(125)I]Iodo-DPA-713 accumulates specifically in tuberculosis-as

169 losis and evaluated using whole-body [(125)I]iodo-DPA-713 single-photon emission computed tomography

170 atios were significantly higher with [(125)I]iodo-DPA-713 SPECT (4.06 +/- 0.52) versus [(18)F]fluorod

171 [(125)I]Iodo-DPA-713 SPECT imaging clearly delineated tuberculos

172 [(125)I]Iodo-DPA-713 SPECT provides higher lesion-specific signa

173 data support the application of both (125)I-iodo-DPA-713 SPECT/CT and DPA-713-IRDye800CW near-infrar

174 Pancreatic (125)I-iodo-DPA-713 uptake was significantly higher in treated

175 The biodistribution of (125)I-iodo-DPA-713 was determined under the same conditions, a

176 zolo[1,5-a]pyrim idin-3-yl)acetamide ((125)I-iodo-DPA-713) SPECT/CT or (18)F-FDG PET/CT.

177 ic pancreatitis, we hypothesized that (125)I-iodo-DPA-713, a small-molecule radiotracer that specific

178 imaged using a fluorescent analog of (125)I-iodo-DPA-713, DPA-713-IRDye800CW, for correlative histol

179 Using photoreactive DNA containing 5-iodo-dUMP in defined positions, XPC/Rad4 location on dam

180 Silver-mediated annulation of 2-iodo enol esters leading to 4- and 3,4-substituted isoco

181 The resultant iodo-enol esters were subsequently coupled with boronic

182 lement of the approach entailed treatment of iodo-epoxide 7, prepared by N-alkylation of 6 with (S)-g

183 C2 analogues, including the chloro-, bromo-, iodo-, fluoro-, and methyl-substituted analogues, but do

184 uorophore dyads were synthesized by coupling iodo-functionalized dithiahomoporphyrin with an ethynyl-

185 BA and the Vasella-type fragmentation of a 5-iodo furanoside using chromium(II) chloride when zinc pr

186 g agent, and by direct radioiodination using IODO-GEN ((125)I-Nanobody).

187 An IODO-GEN-based remote labeling system was used.

188 NMR spectroscopic methods revealing extended iodo Gilman cuprates.

189 of allyl chloride into a THF-d8 solution of iodo-Gilman reagent, Me2CuLi.LiI (A), spinning in the pr

190 ical method for the synthesis of C-2 deoxy-2-iodo glycoconjugates in self-assembled structures was fo

191 2-Iodo glycoserinyl esters were intramolecularly converted

192 an S(N)2' solvolysis process to displace the iodo group affords a fused polycyclic compound.

193 species differing in the positioning of the iodo group relative to the hydroxyl which readily underg

194 t N(4) was optimal, and replacement of the 5-iodo group with chloro, bromo, or fluoro groups led to l

195 The iodo groups of diiodide 6 pass through the calixarene ma

196 The stereospecific alkylation of the iodo groups of the resulting di-O-alkylated anti-1,3-dii

197 ity increases across the dihalogenated HBQs: iodo- > bromo- > chloro-HBQs (P < 0.05).

198 A new and extensive set of 4-(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-N-dimethylbenzeneamin

199 f the kibdelones employing an intramolecular iodo halo-Michael aldol reaction and its merger with an

200 hat formation and occurrence of highly toxic iodo-HBQs and 2,5-HBQs warrant further investigation to

201 of pyrido[1,2-a]pyrimidin-4-ones with bromo/iodo-(hetero)arenes under aqueous conditions has been de

202 The hydroamidation and iodo-imidation of ynamides to trisubstituted and tetrasu

203 g agent, 2-(4'-dimethylaminophenyl)-6-(123)I-iodo-imidazo[1,2-a]pyridine ((123)I-IMPY), in adjacent b

204 Other aryl iodides such as 3-iodo-imidazo[1,2-alpha]pyridine were also used for the t

205 The syn iodo-imidazoliophane isomer forms novel dimeric isostruc

206 The protic-, chloro-, and anti iodo-imidazoliophane receptors proved to be ineffectual

207 xperimental observations that bromo- and syn iodo-imidazoliophane XB receptors form stable cooperativ

208 vent mixture demonstrated the bromo- and syn iodo-imidazoliophane XB receptors to bind selectively io

209 isolation of anti and syn conformers of the iodo-imidazoliophane, whereas the chloro- and bromo-imid

210 The receptors contain chloro-, bromo-, and iodo-imidazolium motifs incorporated into a cyclic struc

211 -1-(2-(alkynyl)phenyl)ethanol (6) to furnish iodo isochromene derivatives.

212 aza-2'-deoxyguanosine affording the 7- and 8-iodo isomers.

213 cope of the radical precursor includes alpha-iodo ketones, esters, nitriles, primary amides, alpha-fl

214 , 3,3'-diiodo-l-thyronine (3,3'-T(2)), and 3-iodo-l-thyronine (3-T(1)), in the brain and thyroid glan

215 Tri-iodo-l-thyronine (T(3)) suppresses the proliferation of

216 Tri-iodo-L-thyronine (T3) treatment of cultured cardiomyocyt

217 Inhibiting 3,5,3'-tri-iodo-L-thyronine and 3,5,3',5'-tetra-iodo-L-thyronine se

218 ,3'-tri-iodo-L-thyronine and 3,5,3',5'-tetra-iodo-L-thyronine secretion did not alter isoform switchi

219 ructures of human IYD and its complex with 3-iodo-l-tyrosine illustrate the ability of the substrate

220 pathway involving an attack of XeF(2) at the iodo ligand of Pt(II) aryl iodo complexes to generate I-

221 The initial iodo-Mannich products were found to be readily cyclized

222 tal-free, visible-light, radical (trifluoro)(iodo)methylations of alkenes, illustrated by their use a

223 eatment with a 5-HT1A-specific antagonist, 4-iodo-N-[2-[4(methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyr

224 The reactions of a wide range of 2-iodo-N-phenyl benzamides and acyclic diketones as starti

225 The preparation of C-iodo-N-Ts-aziridines with excellent cis-diastereoselecti

226 ed, selectively affording either novel alpha-iodo-N-Ts-imines or alpha-iodo-aldehydes in high yield.

227 of melting triphenylphosphine with the gamma-iodo NHBoc-amino ester, derived from L-aspartic acid.

228 was prepared by reacting 2-trifluoromethyl-4-iodo-nicotinic acid (2) with amidine 9a catalyzed by Pd(

229 , which reacts with nitronates to form alpha-iodo nitroalkanes as precursors to the amides.

230 The 1-N-benzyl-5-iodo(or bromo)uracil undergoes Pd-catalyzed [Pd2(dba)3]

231 o 86% yield via the catalytic reduction of 1-iodo- or 1-bromo-5-decyne by [[2,2'-[1,2-ethanediylbis(n

232 ed by stannyldesulfonylations and subsequent iodo- or protiodestannylation gave 6-N-cyclopropyl-5'-de

233 [Bis(trifluoroacetoxy)iodo]perfluoroalkanes C(n)F(2n+1)I(OCOCF(3))(2) (n = 4,

234 ly converted to the stable [hydroxy(tosyloxy)iodo]perfluoroalkanes, C(n)F(2n+1)I(OH)OTs, by treatment

235 ould be readily converted into various alpha-iodo-perfluorocarboxylic acid derivatives or telomerized

236 The classic 4-azido-3-iodo-phenyl group was appended to either the C-1 or C-5

237 6'-dimethyl-morpholino)-3-(4-azido-3-[(125)I]iodo-phenyl)propane ([(125)I]IAF), which covalently deri

238 specificity in AcKRS and in a PylRS variant [iodo-phenylalanyl-tRNA synthetase (IFRS)] that displays

239 (N()-acetyllysyl-tRNA synthetase [AcKRS], 3-iodo-phenylalanyl-tRNA synthetase [IFRS], a broad specif

240 otic stress were attenuated by 2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benz

241 '-methoxyflavone)-, PD184352- [2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benz

242 The iodo photosensitizer 2 (nonlabeled analogue of 4) produc

243 ed with [3H]prazosin, [3H]RX21002 and [125I]-iodo-pindolol autoradiography, respectively.

244 ultraviolet photolysis of the corresponding iodo precursors in a mixture of water and methanol at va

245 Mono-iodo-ProTx-II ((125)I-ProTx-II) binds with high affinity

246 f pyrrolo[3,2,1-de]acridones 4a-v, 5a-h from iodo-pyranoquinolines 2a-i by the palladium-catalyzed re

247 ctionalized azido-pyranoquinolines and azido-iodo-pyranoquinolines via electrophilic cyclization of o

248 eds with excellent regiocontrol to provide 5-iodo pyrazoles.

249 ing of acrylanilides with 4-bromo-2-chloro-3-iodo-pyridine using palladium acetate can produce bis-He

250 [(18)F]6), and 2-(3-[1-carboxy-5-[(5-[(125)I]iodo-pyridine-3-carbonyl)-amino]-pentyl]-ureido)-pe ntan

251 nd an iodolactonization reaction to form the iodo pyrrolizidinone fragment of the molecule is describ

252 Substitution of 2-Cl with iodo reduced protection in the CSQ model.

253 The TRPV1 inhibitor, iodo-resiniferatoxin (1 microM), also partially inhibite

254 receptor potential vanilloid-1 antagonist, 5-iodo-resiniferatoxin (1 microM, approximately 80% reduct

255 Likewise, the antagonist 5-iodo-resiniferatoxin (5-iodo-RTX) displayed a Ki of 4.2

256 itor ruthenium red, and the TRPV1 antagonist iodo-resiniferatoxin (I-RTX).

257 potential discharge, and the combination of iodo-resiniferatoxin and NFA virtually abolished the BK-

258 The inhibitory effect of 5-iodo-resiniferatoxin on acid-induced increases in calciu

259 Subunit-specific antagonism (iodo-resiniferatoxin) and agonism (capsaicin) were used

260 030031), but unaffected by the TRPV1 blocker iodo-resiniferatoxin.

261 d current was evoked that was inhibited by 5-iodo-resiniferatoxin.

262 se, the antagonist 5-iodo-resiniferatoxin (5-iodo-RTX) displayed a Ki of 4.2 pM if incubated with CHO

263 oupled to the 3-bromo-5-iodo arene using the iodo selective Pd(tri-2-furylphosphine)4 catalyst in con

264 The best yields of 4-iodo-selenophenes were obtained with iodine as a halogen

265 sters were intramolecularly converted into 2-iodo serinyl glycosides which upon dehalogenation gave C

266 tion reaction to provide the corresponding 3-iodo spirocyclohexadienones.

267 he need for an electronically enriched ortho-iodo substituent in catalyst 4f supports a recent theore

268 The iodo substituent in fluorinated 4-iodofurans was utilize

269 (1)H NMR studies suggest that the bulky iodo-substituent packs within a nonpolar interchain crev

270 , hydroxy, azido, imidazole, thiophenyl, and iodo substituents.

271 of low-valent Ni(0/I) species with specific iodo substituted N^O (Ar-I) ligands were shown to initia

272 and 2 equiv of NIS at refluxing CH2Cl2 gave iodo-substituted benzo[b]naphtho[2,1-d]thiophene (6) in

273 collected on Br2B-PMHC and related bromo and iodo-substituted BODIPY dyes show that the trap segment

274 Iodo-substituted compounds generated by the electrophili

275 nase inhibition and enabled the design of 10-iodo-substituted derivatives as very potent DYRK1A inhib

276 A synthesis of iodo-substituted dibenzocyclohepten-5-ones by the iodine

277 thodology can also be extended to the use of iodo-substituted imines to produce novel spirocyclic bet

278 Selected iodo-substituted tetrahydro-3H-cyclopenta[c]quinolines e

279 A series of iodo-substituted tetrahydro-3H-cyclopenta[c]quinolines w

280 cked architecture of the EtCN solvate of the iodo-substituted, oxobenzene-bridged bisdithiazolyl radi

281 5-Iodo substitution of the uracil ring of 44a gave 45, whi

282 bicyclo sugar intermediate, followed by an N-iodo-succinimide-induced stereoselective nucleosidation.

283 The 4-iodo-thiophenes were exclusively obtained by using dimet

284 sulin (-54%), adiponectin (-49%), 3,5,3'-tri-iodo-thyronine (T3) (-39%), and testosterone (-11%).

285 TPN-Y1/K12/Q13 and mono-iodo-TPN-Y1/K12/Q13 ([(127)I]TPN-Y1/K12/Q13) inhibit wit

286 ing [3]rotaxane host system containing a bis-iodo triazolium-bis-naphthalene diimide four station axl

287 y of the axle to the central halogen bonding iodo-triazolium station anion recognition sites to form

288 onia addition revealed that the formation of iodo-trihalomethanes (I-THMs), especially iodoform, was

289 e engineered sites in lispro (Tyr(B26)) by 3-iodo-Tyr (i) augments its thermodynamic stability (Delta

290 Remarkably, the 3-iodo-Tyr(B26) modification stabilizes an oligomeric form

291 By exploiting this allosteric switch, 3-iodo-Tyr(B26)-lispro thus illustrates how a nonstandard

292 re observed in the crystal structure of a 3-[iodo-Tyr(B26)]insulin analog (determined as an R6 zinc h

293 ook quantitative atomistic simulations of 3-[iodo-Tyr(B26)]insulin to predict its structural features

294 hyl-DOPA and 0.75 mg/g of the TH inhibitor 3-iodo-tyrosine (3-IT) resulted in 20% pupae with partiall

295 it is shown that modification of tyrosine to iodo-tyrosine followed by UV photodissociation of the ca

296 , and Phe(11) or m-I-Tyr(11) (m-I-Tyr = mono-iodo-tyrosine).

297 UVPD of iodo-tyrosine-modified peptides was used to generate loc

298 5-Iodo-UDP 32 (EC50 = 0.15 microM) was equipotent to UDP,

299 Two different scaffold types, one a bicyclic iodo-vinylidene tertiary amine/tertiary alcohol and the

300 ility of (111)In-PSMA-I&T ((111)In-DOTAGA-(3-iodo-y)-f-k-Sub(KuE)) (PSMA is prostate-specific membran